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Background / Objective: 
Overlapping clinical symptoms often complicate differential diagnosis between 
patients with Alzheimer’s disease (AD) and behavioral variant frontotemporal 
dementia (bvFTD). Magnetic resonance imaging (MRI) reveals disease specific 
structural and functional differences that aid in differentiating AD from bvFTD 
patients. However, the benefit of combining structural and functional connectivity 
measures to – on a subject-basis - differentiate these dementia-types is not yet known.  
Methods: 
Anatomical, diffusion tensor (DTI), and resting-state functional MRI (rs-fMRI) of 30 
patients with early stage AD, 23 with bvFTD, and 35 control subjects were collected 
and used to calculate measures of structural and functional tissue status. All measures 
were used separately or selectively combined as predictors for training an elastic net 
regression classifier. Each classifier’s ability to accurately distinguish dementia-types 
was quantified by calculating the area under the receiver operating characteristic 
curves (AUC). 
Results: 
Highest AUC values for AD and bvFTD discrimination were obtained when mean 
diffusivity, full correlations between rs-fMRI-derived independent components, and 
fractional anisotropy (FA) were combined (0.811). Similarly, combining gray matter 
density (GMD), FA, and rs-fMRI correlations resulted in highest AUC of 0.922 for 
control and bvFTD classifications. This was however not observed for control and 
AD differentiations. Classifications with GMD (0.940) and a GMD and DTI 
combination (0.941) resulted in similar AUC values (P=0.41). 
Conclusion: 
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Combining functional and structural connectivity measures improve dementia-type 
differentiations and may contribute to more accurate and substantiated differential 
diagnosis of AD and bvFTD patients. Imaging protocols for differential diagnosis 
may benefit from also including DTI and rs-fMRI. 
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Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) 
are the most common causes of young onset dementia [1–3]. Accurate and confident 
differentiation between these disease types is crucial for the proper management, 
prognosis, and potential treatment of patients with dementia [4–6]. Yet, despite 
distinct clinical diagnostic criteria [1,7], heterogeneity and overlap of clinical 
manifestations often complicate differential diagnosis [8].  
 
Complementary to clinically derived correlates, magnetic resonance imaging (MRI) 
has shown to reveal important disease-specific brain changes that may corroborate 
differential diagnosis on an individual basis [9]. Differences in the extent and location 
of gray matter (GM) and white matter (WM) atrophy have been recognized as 
important markers that distinguish each dementia-type [10–14]. Additionally, varying 
levels of diffusion tensor imaging (DTI)-derived measures elucidate regional 
differences in WM integrity impairment that are specific to AD or bvFTD patients 
[15–17]. It even has been suggested that these integrity impairments may precede or 
facilitate cortical degeneration [18]. However, despite these detectable group 
differences, MRI-based single subject classifications remain challenging. Per subject 
analyses are affected more by between subject variations than group-based analyses 
and it is still unclear which MRI measure contributes most to MRI-based dementia-
type classifications [18–20]. Particularly in the earlier disease stages, accurate 
dementia-type classifications based on structural neuroimaging alone may be 
hampered by atrophy and tract specific deficit patterns that overlap or are hardly 
distinguishable [17,21,22].  
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Functional connectivity measures may inform on dementia state [23–25] or dementia 
progression [23–25] even well before clinical or structural differences can be detected 
[25,26]. Differences in functional connectivity strengths as measured with resting-
state functional MRI (rs-fMRI) have been heralded as early and useful markers to 
differentiate AD and bvFTD patients [27,28]. However, the contribution of rs-fMRI 
measures as a (complementary) measure to differentiate dementia-types on an 
individual basis is still largely unclear [27,29,30].  
 
It may be argued that one single MRI-derived measure may not sufficiently capture 
the complex pathophysiological processes that underlie dementia development. 
Multiparametric MRI-based statistical algorithms integrate various MRI measures to 
compute a single, quantitative probabilistic index and have shown to be more accurate 
in differentiating cognitively healthy from demented patients than single MRI 
measure-based algorithms alone [18,19,29,31,32]. We speculate that MRI-based 
classification algorithms that differentiate dementia-types benefit from integrating 
structural and functional connectivity measures. In this study we therefore aimed to 
determine the diagnostic accuracy of MRI-based classification algorithms to, on a 
subject basis, differentiate between AD and bvFTD patients, when combining 





This two-center study involved a retrospective analysis of data previously published 
[18,28] and was conducted in accordance with regional research regulations and 
conformed to the Declaration of Helsinki. Local medical ethics committees of both 
centers approved the study and all patients gave written informed consent for their 
clinical and biological data to be used for research purposes. 
For this study, we selected 37 patients with probable AD and 28 patients with bvFTD, 
who visited either the Alzheimer Center of the VU University Medical center (VUmc) 
(AD: n=22, bvFTD: n=19) or the Alzheimer Center of the Erasmus University 
Medical Center Rotterdam (EMC) (AD: n=15, bvFTD: n=9). In addition, we included 
40 cognitively normal controls that were recruited by local newspaper advertisements 
(VUmc: n=22; EMC: n=18).  
Patients underwent a standardized one-day assessment including medical and 
informant-based history, medical history (dementia, psychiatry, cardiovascular) of 
first-degree relatives, physical and neurological examination, blood tests, 
neuropsychological assessment, and brain MRI. Diagnoses were made in a 
multidisciplinary consensus meeting according to the core clinical criteria of the 
National Institute on Aging and the Alzheimer’s Association workgroup for probable 
AD [7] and according to the clinical diagnostic criteria of FTD for bvFTD [1]. To 
minimize center effects, all diagnoses were re-evaluated in a panel that included 
clinicians from both centers. Controls were screened for memory complaints, family 
history of dementia, drugs- or alcohol abuse, major psychiatric disorder, and 
neurological or cerebrovascular diseases. They underwent an assessment that included 
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medical history, physical examination, neuropsychological assessment, and brain 
MRI comparable to the patient work-up.  
For both cohorts inclusion criteria were: (1) age between 40 and 80 years and (2) 
availability of a T1-weighted 3-dimensional MRI (3DT1w) scan, a diffusion tensor 
imaging (DTI) dataset, and a rs-fMRI T2*-weighted scan. Exclusion criteria were: (1) 
large image artifacts (n=7); (2) failure of imaging analyzing software to process MR 
scans (n=10); and (3) gross brain pathology other than atrophy, including severe white 
matter hyperintensities and/or lacunar infarctions in deep gray matter structures.  
 
MRI acquisition and review 
Patients and controls of the VUmc cohort were scanned at the VUmc Amsterdam 
using a 3T MRI scanner (Signa HDxt, GE Healthcare, Milwaukee, WI, USA) with an 
8-channel head coil with foam padding to restrict head motion. Patients and controls 
of the EMC cohort were scanned at the Leiden University Medical Center (LUMC) 
using a 3T MRI scanner (Achieva, Philips Medical Systems, Best, The Netherlands) 
with an 8-channel SENSE head coil. MRI sequence parameter settings are detailed in 
Supplementary Table 1. In brief, the imaging protocol included a whole-brain near-
isotropic 3D T1-weighted (3DT1w) sequence for cortical and subcortical tissue-type 
segmentation, a diffusion tensor imaging (DTI) sequence for assessments of white 
matter integrity, and a resting state functional MRI T2*-weighted MRI for the 
calculation of functional connectivity measures. Participants were instructed to lie still 
with their eyes closed and not to fall asleep during rs-fMRI. Additionally, a 3D fluid 
attenuated inversion recovery, dual-echo T2-weighted, and susceptibility weighted 
imaging datasets were acquired to allow for review of brain pathology other than 




Preprocessing of 3DT1w images involved non-uniformity correction [33] and 
segmentation of parenchymal tissue signal from surrounding tissue [34]. Images were 
then spatially aligned to the MNI152 2x2x2 mm T1 template (Montreal Neurological 
Institute, Canada) using a non-linear registration procedure with a warp resolution of 
10 mm [35].  Voxel-wise densities GM, WM, and cerebrospinal fluid (CSF) were 
determined with the initial steps of the voxel-based morphometry pipeline of the 
Statistical Parametric Mapping toolbox (SPM12; Functional Imaging Laboratory, 
University College London, London, UK)[36] implemented in MATLAB R2015b 
(MathWorks, Natick, MA). Except for manual placement of the image’s origin 
approximately on the anterior commissure and applying the light cleanup option to 
remove any remaining non-brain tissue, default settings were used for tissue-type 
segmentations. Deep gray matter (DGM) structures including the bilateral thalamus, 
caudate nucleus, putamen, globus pallidus, nucleus accumbens, amygdala, and left 
and right hippocampus were separately identified using a dedicated registration and 
segmentation procedure with default settings [37].  
 
For DTI, preprocessing included motion and eddy-current induced distortion 
correction and gradient vector direction correction [38]. The corrected DTIs were 
subsequently used to voxel-wise calculate measures of fractional anisotropy (FA), 
mean diffusivity (MD), axial diffusivity ( ; largest eigenvalue), and radial 
diffusivity ( ; average of the two eigenvalues 2 and 3) using weighted least 
square fitting [39]. The tract-based spatial statistics (TBSS) pipeline was used to 
create a study-specific TBSS-skeleton, by non-linearly aligning all FA maps to the 
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FMRIB58_FA template [40]. The derived skeleton was thresholded at 0.2 to ensure 
values originated from WM tissue (see below).  
 
For rs-fMRI, preprocessing included motion correction [41], brain extraction, spatial 
smoothing using a Gaussian kernel with a full width half maximum of 3 mm, grand 
mean intensity normalization, motion artifact removal, and high-pass temporal 
filtering (cutoff frequency = 0.01Hz).  Motion artifacts were removed from the data 
using the ICA-based automatic removal of motion artifacts (ICA-AROMA (vs0.3-
beta)) procedure [42]. Subsequently, the rs-fMRI volumes were linearly aligned to the 
corresponding 3DT1w [43]. Spatial alignments to the MNI152 template were achieved 
by concatenating the registration parameters of the previous step with the nonlinear 
parameters from the 3DT1w to the MNI152 template. 
 
All registration and segmentation steps were critically reviewed and errors were 
corrected accordingly.  
 
Feature extraction 
Two anatomical atlases were used to parcellate the entire brain. These atlases were 
used to extract, in each subject’s native space, cortical and subcortical GM and WM 
features from the structural 3DT1w-images. The 48 cortical regions of the Harvard–
Oxford (HO) probabilistic anatomical brain atlas were split into left and right 
hemisphere regions, resulting in 96 distinct cortical regions that covered the complete 
cortical GM [44]. For WM regional analysis, we selected 20 WM tract regions from 
the probabilistic Johns-Hopkins-University (JHU) white-matter tractography atlas 
[45]. Voxel probability values less than 25% were excluded. The remaining values 
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were used to weight the WM or GM densities. Weighted GM densities were 
calculated by weighting the GM segmentations by the probability of a voxel being 
part of that specific HO brain atlas-derived region. Weighted WM densities were 
calculated by weighting the WM segmentations by the probability of a voxel being 
part of that specific JHU brain atlas-derived tract. This way we emphasized the 
regions’ likelihood of being GM or WM without introducing bias resulting from 
conservatively selecting brain regions. For DGM regions, the dedicated segmentations 
of DGM, hippocampus, and amygdala were used to calculate the regional volumes 
normalized by intracranial volume to compensate for individual differences in brain 
volume [46]. This resulted in a feature vector of 110 GMD values (96 cortical GMD 
values and 14 DGM volumes), and a feature vector of 20 average WMD values per 
subject. 
 
DTI-based features were calculated by, on a voxel-wise basis, projecting each 
subject’s FA, MD, AxD, or RD values on to the TBSS group skeleton. Analogous to 
the anatomical WMD features, the 20 WM tracts of the probabilistic JHU white-
matter tractography atlas were used to calculate a weighted mean FA, MD, AxD, and 
RD per tract per subject. This resulted in 4*20 feature vectors of mean FA, MD, AxD, 
and RD values per subject.  
 
The functional connectivity features were calculated by combining all processed rs-
fMRI datasets in a temporally concatenated independent component analysis (ICA) 
[47], with dimensionality fixed at 70 components and an ICA threshold of 0.99 [48]. 
This meant that each voxel included in the ICA map was 99 times more likely to be 
part of that component than to be caused by Gaussian background noise. For each 
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subject, we calculated the mean time course for each component, weighted by the 
ICA weight map and GM probability of that component’s region. These mean time 
courses were subsequently used to determine the functional connectivity of a 
component with the 69 other components. Functional connectivity was either 
expressed as full correlations (corr) or as sparse L1-regularized partial correlations 
(pcor) between the components' time courses. Partial correlations were calculated 
using the graphical lasso algorithm [49]. Both functional connectivity measures 




These feature vectors were subsequently used to train an elastic net regression 
algorithm with default settings to provide a statistically sound solution for the 
imbalance between a large number of features and a small number of subjects. An 
elastic net regression model estimates a sparse regression model that selects a subset 
of all the features provided as input by imposing feature selection and feature weight 
penalties during regression, effectively selecting only those features relevant for 
classification [50–52]. A cross validation procedure was used to determine the 
optimal set of penalty parameters and generalized classification performance of the 
elastic net classifiers. Cross-validation reduces classification bias by iteratively 
subdividing the data in separate test and training sets. In this study we used two 
nested, 10-fold cross validation loops. The first, outer, loop was used to determine the 
overall classification performance, while the second, inner, loop subdivided the 
training set further to determine the lowest binomial deviance that corresponded with 
the best operational parameters for the penalty terms (including the optimal number of 
 13 
features) without overestimating classification performance [53,54]. This process was 
repeated 10 times to ascertain that each subject was part of the test set exactly once. 
To ensure that estimated feature regression coefficients were conditional on subject 
age and gender and to adjust for scanner effects, age, gender, and center were 
included into the model without any penalty. For AD and bvFTD differentiations, 
models were furthermore made conditional on disease severity by also including 
disease duration (in months). The entire classification procedure was repeated 50 
times to reduce variance resulting from random partitioning in training and test folds, 
and to report the range of observed outcomes under different train and test conditions.  
 
We trained three types of classification models following the above-described 
procedures. One model aimed to differentiate AD from bvFTD patients. To 
contextualize the classification performance values of this model, we also trained two 
additional models. A second model aimed to differentiate control subjects from 
bvFTD patients, and a third model to differentiate control subjects from AD patients 
For each subject, these models produced a predicted value between 0 and 1. The 
higher the predicted value the more likely this subject belongs to the bvFTD- group or 
AD group in case of the control versus AD model.  
 
Classification performance 
Classification performances were quantified using a threshold-independent measure 
based on receiver-operating characteristic (ROC) analyses. After each 10-fold nested 
cross-validation, the predictions were used to calculate ROC curves by continuously 
increasing a threshold between 0 and 1 and for each threshold classifying a subject 
either as control, AD, or bvFTD patient, depending on the model being evaluated. 
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These classifications were then compared with the subject’s actual differential 
diagnosis. The area under this ROC curve (AUC) was calculated as a measure of 
classification performance insensitive to the distribution of each patient group [55]. 
Additionally, we calculated the optimal operating point on each curve to calculate the 
model’s accuracy, sensitivity, and specificity given equal class distribution and equal 
penalty for false positive and false negative predictions. Reported AUC, accuracy, 
sensitivity, and specificity values are averages obtained from repeating the cross-
validation 50 times. 
 
Multiparametric classifications 
To determine whether combining multiple MRI measures improved classification, we 
first assessed classification performance for each single measure separately by 
alternately providing all features of that specific measure (i.e. 110 GMD, 20 WMD, 
20 FA, 20 MD, 20 AxD, 20 RD, 2514 corr, or 2514 pcor features) as input for cross-
validation. Subsequently, we step-wise concatenated measures each time adding all 
features of a new measure to the best performing measure combination (i.e. highest 
AUC) of the previous step till all measures and thus all features were included into the 
model. The model subsequently determined the importance of each feature by 
assigning the proper weight. 
 
All classification analyses and evaluations were implemented in R (R core 2010, 




Statistical analyses of between-group differences were performed using SPSS (IBM 
SPSS Versions 22.0, IBM, Amonk, NY). Demographic group differences between 
age, MMSE, and disease duration were assessed using analysis of variance 
(ANOVA). Sex and center distributions were assessed with χ2 tests. Permutation 
testing was used to determine whether single or multiparametric models performed 
above-chance level (one-tailed, N=5000). The maximum statistic method was used 
for family-wise error correction [56]. A bootstrap percentile method was used to 
compare ROC curves of single measures (two-tailed, N=5000), and between single 
measures and the best performing multiparametric combination (one-tailed, N=5000) 
[57,58]. False discovery rate correction within each patient-group was used to correct 




For this study, 88 subjects met the inclusion criteria. Thirty AD subjects were 
diagnosed with probable AD, 23 patients with bvFTD. Thirty-five control subjects 
were included for classification performance evaluation of the classification models 
involving control subjects. MMSE values of control subjects were higher than those 
of patients. MMSE values of AD patients were comparable to those of bvFTD 
patients (Table 1).  
 
Classification performance: AD versus bvFTD 
For AD and bvFTD differentiations, combining multiple MRI measures within a 
multiparametric classification model resulted in higher mean AUC values than those 
with models that were based on single MRI-based measures only (Figure 1; Table 2). 
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The level of AUC values was however conditional on the combination being 
considered. After step-wise adding multiple MRI-derived measures to the best 
performing single MRI measure model (i.e. MD: 0.708 [0.625-0.775] (mean AUC 
[min-max]); Table 2 underlined), highest AUC, sensitivity, and specificity values 
were obtained for a classification model that included MD, full correlations, and FA 
(0.811 [0.755 – 0.862]; Table 2: bold; Table 3: bold). When comparing the single 
measure-based classifications, AUC values of the single measure-based classifications 
were not significantly different. However, AUC values obtained with the 
multiparametric model were significantly higher compared with those obtained with 
single MRI measure-based models (Table 3), except for MD-based classifications 
(P=0.06).  
 
Classification performance: control versus dementia 
MRI measures that resulted in highest classification performance rates for control 
versus dementia classifications (i.e. control versus bvFTD or control versus AD) were 
different from those obtained with AD versus bvFTD classifications. For control and 
bvFTD classifications highest AUC, sensitivity, and specificity values were found for 
a multiparametric model that included measurements of FA, GMD, and full 
correlations (0.922 [0.877-0.954]; Table 4: bold; Supplementary Table 2: bold). AUC 
values of this multiparametric model were significantly higher than those obtained 
with single MRI measure-based models, except for FA- (0.862 [0.810-0.903], P=0.08) 
and GMD-based (0.858 [0.827-0.896], P=0.11) classifications (Table 4). For 
classifications between control subjects and AD patients on the other hand, 
classification performance values of a combination of GMD and DTI measures (0.941 
[0.910-0.966]) were not better than classifications based on GM measurements only 
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(0.940 [0.913-0.962] P=0.41) (Table 5, Supplementary Table 3). While the 
combination outperformed the other single measure-based classifications, GMD-
based classifications were also better than all other single MRI measure classification 
except for RD-based classifications (0.832 [0.784-0.865], P=0.10). 
 
Features selected 
MRI-derived measures outweighed the contribution of gender, age, and center to the 
classification. AD and bvFTD differentiations using gender, age, and center 
distributions only did not outperform random chance (AUC=0.596, P=0.12). AUC 
values of the best performing AD versus bvFTD model (i.e. combination of MD, full 
correlations, and FA) were similar to classifications where age (P=0.89), gender 
(P=0.70), or center (P=0.14) was excluded as a covariate. Identical AUC values were 
also obtained when these covariates were excluded from the best performing control 
versus bvFTD model (i.e. combination of FA, GMD, and full correlations: age 
P=0.10, gender P=0.65, center P=0.50) or control versus AD model (i.e. combination 
of GMD, AxD, FA, RD, MD: age P=0.60, gender P=0.64, center P=0.79).  
 
Nested cross-validation resulted in models that selected a subset of all the MRI 
features provided as input for classification. The best performing AD versus bvFTD 
model selected 5% of all the MD, full correlations, and FA features provided for 
classification. This model focused on differences in uncinate fasciculus, forceps 
minor, cingulum bundle, cortical spinal tracts, and altered functional connectivity 
with the dorsal default mode-network. In contrast, the control versus dementia models 
also included GM regions for classification. The best performing control versus 
bvFTD model selected 3% of all provided features and considered anterior thalamic 
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radiation, cortical spinal tract, inferior longitudinal fasciculus, and hippocampal 
regions as key regions for classification. The best performing control versus AD 
model selected 37% of all the features provided and primarily focused on volume 
differences in DGM structures including the hippocampus, nucleus accumbens, 
pallidum, and thalamus. 
Discussion 
 
This study investigated the diagnostic accuracy of MRI-based classification 
algorithms to - on a subject basis – differentiate between AD and bvFTD patients 
using anatomical MRI, DTI, and rs-fMRI. Our study showed that, classification 
algorithms that combine measures of DTI and rs-fMRI are more effective in 
discriminating AD from bvFTD patients than algorithms that use DTI, GMD, or rs-
fMRI measures separately. Furthermore, when compared with classification models 
that aim to differentiate patients from controls we found that the level of improvement 
was conditional on MRI measure and dementia-type differentiation being considered.  
 
GM- and DTI-derived measures have been heralded as important corroborating 
measures for differentiating AD and bvFTD patients [15,18,19,31]. Classification 
methods that combined these measures invariably showed improvement of 
classification accuracy over models that used these measures separately [15,18,31]. 
We also found that combining measures improves classification accuracy. However, 
we found highest classification rates when DTI and rs-fMRI measures were 
combined. GM-based values contributed - either as a single (for AD) or 
complementary measure (for bvFTD) - to the differentiation of dementia versus 
control subjects, but not to the discrimination of AD and bvFTD patients. Differential 
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diagnosis between dementias may be challenged by overlapping GM atrophy patterns 
particularly in subcortical regions [21,22]. Both best performing dementia versus 
control models considered volume reductions in subcortical regions like the 
hippocampus as decisive regions for classification and may therefore have had little 
contribution in the differentiation between the dementia-types. Distinct 
microstructural changes in WM may be potential markers for bvFTD. Compared with 
AD patients, bvFTD patients show distinct differences in diffusion especially in key 
regions like uncinate fasciculus, genu of the corpus callosum, and cingulum bundle 
[16,17,59]; differences that may even precede cortical degeneration [26]. In line with 
these findings, we found that the best performing bvFTD classification models 
specifically focused on these regions of DTI-derived WM pathology. We also found 
that AD versus bvFTD classifications improved when rs-fMRI measures were added. 
Altered connectivity measurements mainly with the dorsal default mode network 
regions were considered important and in the end increased classification 
performance rates. This corresponds with other work that showed that connectivity 
deviations of the default mode network alongside salience / executive control network 
contrast between AD and bvFTD patients [12,27,28,60]. Nevertheless, the role of rs-
fMRI as a separate measure for disease-type classifications has not yet been 
established. It has found limited application for single subject disease-type 
classifications [27,29,30,32]. In AD versus control classifications its performance 
rates are consistently among the lowest compared with other MRI measures 
[29,30,32] and we also found that rs-fMRI as a single measure was neither effective 
in differentiating dementia types nor between patients and controls subjects. 
 
We first trained classifications models with varying combinations of MRI measures to 
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differentiate AD from bvFTD patients. Subsequently, we trained models that aimed to 
differentiate AD or bvFTD patients from cognitively healthy controls in order to 
assess classification model accuracy under conditions where large MRI-based 
differences are expected [10,14,15,17,18,28]. Combining MRI-derived structural and 
functional measures improves bvFTD classifications. The level of improvement is 
however dependent on the dementia-types and MRI measures being considered. 
Substantial improvement was for instance not observed for AD versus control 
classifications while others did [29,32] or did not show benefit [30] from GM, DTI, 
and rs-fMRI measures. Furthermore, in line with previous work, we observed that 
concatenating all measures did not result in the most accurate classification model and 
as more measures were added the level of improvement became less apparent 
[29,31,61]. The marginal improvements observed for some measures or combinations 
may indicate a negligible contribution to the model. These may result from variability 
due to non-stationarities like correlation across features and samples within our data. 
[62] These measures are most likely of clinically insufficient added relevance, and 
may not justify the additional processing time.  
 
Overall, classification performance values for dementia-type differentiations where 
consistently lower than dementia versus control subject differentiations. Dementia 
type classifications remain challenging. Compared with control versus patient 
comparisons, differences between patients are more subtle and, particularly in the 
earlier stages of the disease, may be hindered by overlapping patterns of GM atrophy 
[21,22,63], WM integrity impairment [17], or comparable patterns of functional 
connectivity loss in specific functional network regions [12,28]. It remains 
questionable whether any of these algorithms can fully capture the complexity of 
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structural and functional dynamics of neurodegenerative processes underlying 
dementia. We speculate that other algorithms that utilize more sophisticated feature 
combination approaches, like sparse group lasso models [61], or hierarchical or 
longitudinal algorithms that aim to differentiate patients from a general population in 
order to subsequently differentiate between dementia-types may further exploit and 
weigh the additional information from multiple measures [64]. Incorporating other or 
additional imaging-derived biomarkers as cerebral blood flow [65], amplitude of low 
frequency fluctuations [32], GM derived connectomics [19], or diffusion tractography 
derived graph-based analytics [61] may further contribute to MRI-based dementia-
type classification estimates without increasing diagnostic complexity. 
 
In our analysis, we took several steps to reduce classification bias and augment 
generalizability of our results. First, while specific functional network connections 
were found to deviate between AD and bvFTD patients [12,27,28,60], we 
hypothesized that restricting our analysis to specific network regions may introduce 
bias and may unnecessary exclude other regions that show deficits at different stages 
of the disease [23,24,52,66]. The number of network regions that need to be 
distinguished to optimally differentiate between dementia-types still needs 
clarification. ICA dimensionality continues to be an actively debated topic and is a 
trade-off between detail in functionally connected regions and feature space 
dimensionality. Second, we employed a repeated nested cross validation approach in 
which two levels of data segregation ensured unbiased operational parameter 
optimization and classification performance estimation [53]. Thirdly, for 
classification, we used regularized regression to establish homogeneous and stable 
dementia type estimates and to accommodate proper selection of relevant features 
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despite high dimensionality and collinearity of our data [52]. Our study was limited 
by the clinical diagnoses used to validate the differentiations. While our 
multidisciplinary, multicenter team carefully diagnosed each patient according to the 
newest criteria for AD [7] or bvFTD [1], uncertainty in the diagnosis remains. 
Overlapping clinical symptoms may complicate dementia-type differentiations [8] 
and postmortem pathological data to confirm the diagnosis were unavailable. 
Furthermore, we included patients with possible and probable FTD diagnosis to 
maximize our patient cohort. This may have increased the complexity of our 
classifications. We included relatively young patients who were diagnosed in a 
relatively early stage of the disease, therefore likely to have less apparent structural or 
functional deficits. Nevertheless, we were able to differentiate bvFTD patients from 
controls with high accuracy. Further validations with larger, multicenter cohorts are 
necessary to contextualize and compare our findings. The trained models depend on 
both random and non-random class differences in the training sample and especially 
in light of our limited population sizes, we cannot reliably differentiate between real 
and random class differences in the trained models [62]. Consequently, we refrained 
from biological interpretation of the model’s parameters, speculating on the exact 
measure order, and cautiously interpreted the features selected for classification. 
 
In conclusion, in this study we investigated whether multiparametric MRI improves 
MRI-based differential diagnosis of dementia-types with overlapping clinical 
symptoms. We found that combining multiple MRI-derived measures of structural 
and functional connectivity improve MRI-based differentiations between bvFTD and 
AD patients. Our results imply that current MRI protocols for differential diagnosis of 
AD or bvFTD may benefit from adding functional and diffusion connectivity 
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measures complementary to the anatomical (GM-based) measurements already being 
acquired. Yet, the MRI measures and dementia-types being differentiated should be 
carefully considered to attain most optimal result. These results furthermore highlight 
the potential of these multiparametric imaging-based classification algorithms to aid 
in and possibly improve diagnosis, particularly in situations where experienced 
neuroradiologists or other supporting diagnostic measures are available to a limited 
extent. Further analysis should reveal how these results generalize to larger cohorts, to 
cases where patients' symptoms are less conspicuous, or involve subjects in a pre-
symptomatic disease stage. Nevertheless, these observations may serve as a first 
guidance towards integrating quantitative imaging-based measures that may 
contribute to more confident per subject differential diagnoses and subsequent 
tailored patient care. 
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Table 1. Demographics.  
 Control AD bvFTD 
N 35 30 23 
Age 60.8±6.1 66.9±7.8* 63.5±7.6 
Sex (female, n, %) 16 (45.7%) 12 (40.0%) 6 (26.1%) 
MMSE 28.8±1.5 23.4±3.1* 24.5±3.2* 
Disease duration (months) 0.0±0.0 35.2±24.9* 52.9±52.1* 
Center (VUMC, n, %) 21 (60.0%) 20 (66.7%) 16 (69.6%) 
 
*versus control subjects, p<0.01 
Mean ± standard deviation or n (%). AD: Alzheimer’s disease, bvFTD: behavioral 




Table 2. Mean AUC values for AD versus bvFTD classifications using single or combination of multiple MRI-derived measures 
 
 MRI Measure 
 Combined with: MD corr FA GMD AxD pcor RD WMD 
- 0.708 0.674 0.623 0.614 0.636 0.561 0.652 0.614 
MD  0.803 0.707 0.637 0.656 0.631 0.665 0.712 
MD + corr   0.811 0.806 0.801 0.800 0.805 0.809 
MD + corr + FA    0.806 0.797 0.805 0.803 0.806 
MD + corr + FA + GMD     0.807 0.802 0.804 0.800 
MD + corr + FA + GMD + AxD      0.810 0.805 0.808 
MD + corr + FA + GMD + AxD + pcor       0.803 0.801 
MD + corr + FA + GMD + AxD + pcor + RD        0.801 
 
 
Multiparametric models result from stepwise adding measures to the best performing classification model of the previous step, starting with the 
best performing single MRI measure (i.e. MD, underlined). Bold: best performing model. Italic: mean AUC significantly above chance level 
 37 
after family-wise error rate correction. GMD: gray matter density, WMD: white matter density, FA: fractional anisotropy, MD: mean diffusivity, 
AxD: axial diffusivity, RD: radial diffusivity, corr: full correlations between ICA components, pcor: L1-regularized partial correlations between 
ICA components, AUC: area under the ROC curve.
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Table 3. Classification performance values of AD versus bvFTD classifications using single or multiple MRI-derived measures. 
Measure AUC Min - Max Sensitivity Specificity Accuracy Cutoff 
GMD 0.614* 0.535 - 0.722 0.642 0.651 0.647 0.448 
WMD 0.614* 0.533 - 0.712 0.657 0.635 0.645 0.451 
FA 0.623* 0.530 - 0.725 0.670 0.635 0.650 0.449 
MD 0.708# 0.625 - 0.775 0.740 0.710 0.723 0.439 
AxD 0.636* 0.554 - 0.713 0.672 0.649 0.659 0.435 
RD 0.652* 0.557 - 0.730 0.710 0.652 0.677 0.434 
corr 0.674#* 0.599 - 0.767 0.656 0.657 0.657 0.455 
pcor 0.561* 0.455 - 0.639 0.597 0.652 0.628 0.448 
MD + corr + FA 0.811## 0.755 - 0.862 0.746 0.801 0.777 0.425 
 
Mean, minimum, and maximum area under the ROC curve (AUC) after 50 times 10-fold cross-validation. Bold: best performing model, 
Underlined: best performing single measure-based model. Mean sensitivity, specificity, and classification accuracy were derived from the 
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optimal operating point on the ROC (cutoff). GMD: gray matter density, WMD: white matter density, FA: fractional anisotropy, MD: mean 
diffusivity, AxD: axial diffusivity, RD: radial diffusivity, corr: full correlations between ICA components, pcor: L1-regularized partial 
correlations between ICA components, AUC: area under the ROC curve. *P<0.05 versus multiparametric model, #P<0.05 versus chance, 
##P<0.001 versus chance.
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Table 4. Classification performance values of control versus bvFTD classifications using single or multiple MRI-derived measures. 
 
Measure AUC Min - Max Sensitivity Specificity Accuracy Cutoff 
GMD 0.858## 0.827 - 0.896 0.806 0.865 0.841 0.400 
WMD 0.584* 0.504 - 0.655 0.601 0.633 0.620 0.399 
FA 0.862## 0.810 - 0.903 0.842 0.845 0.844 0.427 
MD 0.614*# 0.508 - 0.708 0.628 0.621 0.624 0.399 
AxD 0.723*# 0.599 - 0.779 0.676 0.727 0.707 0.396 
RD 0.809*## 0.763 - 0.858 0.793 0.765 0.776 0.383 
corr 0.648* 0.534 - 0.716 0.649 0.658 0.654 0.387 
pcor 0.613* 0.504 - 0.729 0.563 0.708 0.651 0.414 




Mean, minimum, and maximum area under the ROC curve (AUC) after 50 times 10-fold cross validation. Bold: best performing model. 
Underlined: best performing single measure-based model. Mean sensitivity, specificity, and classification accuracy were derived from the 
optimal operating point on the ROC (cutoff). GMD: gray matter density, WMD: white matter density, FA: fractional anisotropy, MD: mean 
diffusivity, AxD: axial diffusivity, RD: radial diffusivity, corr: full correlations between ICA components, pcor: L1-regularized partial 
correlations between ICA components, AUC: area under the ROC curve. Bold: best performing model, *P<0.05 versus multiparametric model, 






 Table 5. Classification performance values of control versus AD classifications using single or multiple MRI-derived measures. 
Measure AUC Min - Max Sensitivity 
Specificit
y Accuracy Cutoff 
GMD 0.940## 0.913 - 0.962 0.901 0.899 0.900 0.384 
WMD 0.722##§* 0.644 - 0.770 0.691 0.671 0.681 0.406 
FA 0.777§* 0.734 - 0.811 0.745 0.729 0.736 0.435 
MD 0.670#§* 0.601 - 0.734 0.623 0.713 0.671 0.512 
AxD 0.790§* 0.731 - 0.821 0.704 0.787 0.749 0.459 
RD 0.832* 0.784 - 0.865 0.827 0.749 0.785 0.369 
corr 0.708#§* 0.641 - 0.738 0.631 0.792 0.718 0.527 
pcor 0.657§* 0.621 - 0.704 0.630 0.677 0.655 0.481 
GMD + AxD + FA + RD + MD 0.941 0.910 - 0.966 0.898 0.904 0.901 0.402 
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Mean, minimum, and maximum area under the ROC curve (AUC) after 50 repetitions. Bold: best performing model. Underlined: best 
performing single measure-based model. Mean sensitivity, specificity, and classification accuracy were derived from the optimal operating point 
on the ROC (cutoff). GMD: gray matter density, WMD: white matter density, FA: fractional anisotropy, MD: mean diffusivity, AxD: axial 
diffusivity, RD: radial diffusivity, corr: full correlations between ICA components, pcor: L1-regularized partial correlations between ICA 
components, AUC: area under the ROC curve. Bold: best performing model, *P<0.05 versus multiparametric model, §P<0.05 versus GMD, 
#P<0.05 versus chance, ##P<0.001 versus chance. 
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Figure 1. Receiver-operating characteristic curves of classifications between AD and bvFTD patients. 
For each differential diagnosis, measurements of gray matter density (GMD), white matter density 
(WMD), fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AxD), radial diffusivity 
(RD), full correlation between rs-fMRI derived independent components (cor), and L1-regularized 
partial correlation between rs-fMRI-derived independent components (pcor) were separately assessed. 
The multiparametric curve resulted from step-wise combining MRI measures, each time adding a 
measure to the combination with the highest AUC values of the previous step. Highest AUC was 
obtained by combining MD, corr, and FA measurements (mean AUC [min-max]) 0.811 [0.755 – 
0.862]). The diagonal line represents random classification performance. 
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Supplementary Material 
Supplementary Table 1. MRI sequence parameter settings 
 Slices TR (ms) TE (ms) Flip Angle (°) Matrix (mm) Voxel size (mm) Duration (min) 
VUmc (Signa HDxt, GE Healthcare)     
3DT1w 180 7.8  3 12 256 x 256 0.98 x 0.98 x 1.00 4.57 
DTI* 45 13000 87.8 90 128 x 128 2.00 x 2.00 x 2.40 7.48 
rs-fMRI 34 1800 35 80 64 x 64 3.30 x 3.30 x 3.30^ 6.04 
LUMC (Achiva, Philips Medical Systems)    
3DT1w 140 9.8 4.6 8 256 x 256 0.88 x 0.88 x 1.20 4.57 
DTI# 70 8250 80 90 128 x 128 2.00 x 2.00 x 2.00 8.48 
rs-fMRI 38 2200 30 80 80 x 80 2.75 x 2.75 x 2.99^ 7.28 
Scan protocol of whole-brain near-isotropic 3DT1-weighted (3DT1w), diffusion tensor imaging (DTI), and resting state functional MRI T2*-
weighted MRI (rs-fMRI) on 3T scanners at the VU University Medical center (VUmc) and the Leiden University Medical Center (LUMC). 
* 30 directions, b=1000, one b0 image, # 60 directions, b=1000, five b0 images, ^10% interslice gap
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Supplementary Table 2. Mean AUC values for control versus bvFTD classifications using single or combination of multiple MRI-derived 
measures.  
 MRI Measure 
 Combined with: FA GMD corr WMD AxD pcor MD RD 
- 0.862 0.858 0.648 0.584 0.723 0.613 0.614 0.809 
FA   0.918 0.855 0.825 0.865 0.873 0.861 0.861 
FA + GMD    0.922 0.919 0.920 0.914 0.920 0.918 
FA + GMD + corr     0.920 0.917 0.917 0.918 0.915 
FA + GMD + corr + WMD      0.921 0.917 0.918 0.918 
FA + GMD + corr + WMD + AxD       0.920 0.913 0.920 
FA + GMD + corr + WMD + AxD + pcor        0.916 0.915 
FA + GMD + corr + WMD + AxD + pcor +MD         0.918 
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Mean AUC values from 50 times 10-fold cross-validations. Multiparametric models result from stepwise adding measures to the best performing 
classification model of the previous step, starting with the best performing single MRI measure (i.e. FA, underlined). Bold: best performing 
model. Italic: mean AUC significantly above chance level after family-wise error rate correction. GMD: gray matter density, WMD: white 
matter density, FA: fractional anisotropy, MD: mean diffusivity, AxD: axial diffusivity, RD: radial diffusivity, corr: full correlations between 
ICA components, pcor: L1-regularized partial correlations between ICA components, AUC: area under the ROC curve.  
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Supplementary Table 3. Mean AUC values for control versus AD classifications using single or combination of multiple MRI-derived 
measures.  
 MRI measure 
 Combined with: GMD AxD FA RD MD pcor corr WMD 
- 0.940 0.790 0.777 0.832 0.670 0.657 0.708 0.722 
GMD  0.940 0.936 0.935 0.935 0.940 0.938 0.937 
GMD + AxD   0.938 0.938 0.938 0.938 0.936 0.935 
GMD + AxD + FA    0.938 0.935 0.934 0.937 0.936 
GMD + AxD + FA + RD     0.941 0.940 0.936 0.939 
GMD + AxD + FA + RD + MD      0.939 0.936 0.935 
GMD + AxD + FA + RD + MD + pcor        0.937 0.935 
GMD + AxD + FA + RD + MD + pcor + corr         0.936 
 
 49 
Mean AUC values from 50 times 10-fold cross-validations. Multiparametric models result from stepwise adding measures to the best performing 
classification model of the previous step, starting with the best performing single MRI measure (i.e. GMD, underlined). Bold: best performing 
model. Italic: mean AUC significantly above chance level after family-wise error rate correction. GMD: gray matter density, WMD: white 
matter density, FA: fractional anisotropy, MD: mean diffusivity, AxD: axial diffusivity, RD: radial diffusivity, corr: full correlations between 
ICA components, pcor: L1-regularized partial correlations between ICA components, AUC: area under the ROC curve. 
 
